Emile E Voest

Summary

Affiliation: University Medical Center Utrecht
Country: The Netherlands

Publications

  1. pmc Robot-assisted minimally invasive thoraco-laparoscopic esophagectomy versus open transthoracic esophagectomy for resectable esophageal cancer, a randomized controlled trial (ROBOT trial)
    Pieter C Van der Sluis
    Department of Surgery, G04, 228, University Medical Center Utrecht, Heidelberglaan 100, Utrecht, CX, 3584, The Netherlands
    Trials 13:230. 2012
  2. pmc Reduced cilia frequencies in human renal cell carcinomas versus neighboring parenchymal tissue
    Sander G Basten
    Department of Nephrology and Hypertension, University Medical Center Utrecht, Heidelberglaan 100, 3584, CX, Utrecht, The Netherlands
    Cilia 2:2. 2013
  3. doi request reprint Ethical, legal, and counseling challenges surrounding the return of genetic results in oncology
    Martijn P Lolkema
    University Medical Center Utrecht, The Netherlands
    J Clin Oncol 31:1842-8. 2013
  4. pmc Chromothripsis is a common mechanism driving genomic rearrangements in primary and metastatic colorectal cancer
    Wigard P Kloosterman
    Department of Medical Genetics, University Medical Center Utrecht, Universiteitsweg 100, Utrecht, 3584 CG, The Netherlands
    Genome Biol 12:R103. 2011
  5. pmc Are health care professionals able to judge cancer patients' health care preferences correctly? A cross-sectional study
    Hester Wessels
    1Department of Corporate Communications, University Medical Center Utrecht, Heidelberglaan 100, 3508 GA, Utrecht, The Netherlands
    BMC Health Serv Res 10:198. 2010
  6. pmc A randomized two arm phase III study in patients post radical resection of liver metastases of colorectal cancer to investigate bevacizumab in combination with capecitabine plus oxaliplatin (CAPOX) vs CAPOX alone as adjuvant treatment
    Nikol Snoeren
    Department of Surgical Oncology, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands
    BMC Cancer 10:545. 2010
  7. pmc Late release of circulating endothelial cells and endothelial progenitor cells after chemotherapy predicts response and survival in cancer patients
    Jeanine M Roodhart
    Department of Medical Oncology, University Medical Center Utrecht, Utrecht, The Netherlands
    Neoplasia 12:87-94. 2010
  8. doi request reprint Phase I evaluation of telatinib, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in combination with irinotecan and capecitabine in patients with advanced solid tumors
    Marlies H G Langenberg
    Department of Medical Oncology, University Medical Center Utrecht and Science Faculty, Department Pharmaceutical Sciences, Division Drug Toxicology, Utrecht University, Utrecht, The Netherlands
    Clin Cancer Res 16:2187-97. 2010
  9. doi request reprint von Hippel-Lindau tumor suppressor mutants faithfully model pathological hypoxia-driven angiogenesis and vascular retinopathies in zebrafish
    Ellen van Rooijen
    Hubrecht Institute, Royal Netherlands Academy of Arts and Sciences and University Medical Center Utrecht, Utrecht, The Netherlands
    Dis Model Mech 3:343-53. 2010
  10. doi request reprint Accelerated perinecrotic outgrowth of colorectal liver metastases following radiofrequency ablation is a hypoxia-driven phenomenon
    Maarten W Nijkamp
    Department of Surgery, University Medical Center Utrecht, Utrecht, The Netherlands
    Ann Surg 249:814-23. 2009

Collaborators

Detail Information

Publications54

  1. pmc Robot-assisted minimally invasive thoraco-laparoscopic esophagectomy versus open transthoracic esophagectomy for resectable esophageal cancer, a randomized controlled trial (ROBOT trial)
    Pieter C Van der Sluis
    Department of Surgery, G04, 228, University Medical Center Utrecht, Heidelberglaan 100, Utrecht, CX, 3584, The Netherlands
    Trials 13:230. 2012
    ..The objective is to evaluate the efficacy, risks, quality of life and cost-effectiveness of RATE as an alternative to open transthoracic esophagectomy for treatment of esophageal cancer...
  2. pmc Reduced cilia frequencies in human renal cell carcinomas versus neighboring parenchymal tissue
    Sander G Basten
    Department of Nephrology and Hypertension, University Medical Center Utrecht, Heidelberglaan 100, 3584, CX, Utrecht, The Netherlands
    Cilia 2:2. 2013
    ..abstract:..
  3. doi request reprint Ethical, legal, and counseling challenges surrounding the return of genetic results in oncology
    Martijn P Lolkema
    University Medical Center Utrecht, The Netherlands
    J Clin Oncol 31:1842-8. 2013
    ..We also provide a framework for returning these genetic results by proposing a design for a qualified disclosure policy...
  4. pmc Chromothripsis is a common mechanism driving genomic rearrangements in primary and metastatic colorectal cancer
    Wigard P Kloosterman
    Department of Medical Genetics, University Medical Center Utrecht, Universiteitsweg 100, Utrecht, 3584 CG, The Netherlands
    Genome Biol 12:R103. 2011
    ..The significance of these clusters for tumor development or metastatic spread is largely unclear...
  5. pmc Are health care professionals able to judge cancer patients' health care preferences correctly? A cross-sectional study
    Hester Wessels
    1Department of Corporate Communications, University Medical Center Utrecht, Heidelberglaan 100, 3508 GA, Utrecht, The Netherlands
    BMC Health Serv Res 10:198. 2010
    ..We also examined whether there were gender differences between health care professionals with regard to the degree in which they can estimate patients' preferences correctly...
  6. pmc A randomized two arm phase III study in patients post radical resection of liver metastases of colorectal cancer to investigate bevacizumab in combination with capecitabine plus oxaliplatin (CAPOX) vs CAPOX alone as adjuvant treatment
    Nikol Snoeren
    Department of Surgical Oncology, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands
    BMC Cancer 10:545. 2010
    ..This study aims to achieve an improved disease free survival for patients after resection or resection combined with RFA of colorectal liver metastases by adding the angiogenesis inhibitor bevacizumab to an adjuvant regimen of CAPOX...
  7. pmc Late release of circulating endothelial cells and endothelial progenitor cells after chemotherapy predicts response and survival in cancer patients
    Jeanine M Roodhart
    Department of Medical Oncology, University Medical Center Utrecht, Utrecht, The Netherlands
    Neoplasia 12:87-94. 2010
    ..The correlation with a clinical response and survival provides further support for the biologic relevance of these cells in patients' prognosis and stresses their possible use as a therapeutic target...
  8. doi request reprint Phase I evaluation of telatinib, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in combination with irinotecan and capecitabine in patients with advanced solid tumors
    Marlies H G Langenberg
    Department of Medical Oncology, University Medical Center Utrecht and Science Faculty, Department Pharmaceutical Sciences, Division Drug Toxicology, Utrecht University, Utrecht, The Netherlands
    Clin Cancer Res 16:2187-97. 2010
    ....
  9. doi request reprint von Hippel-Lindau tumor suppressor mutants faithfully model pathological hypoxia-driven angiogenesis and vascular retinopathies in zebrafish
    Ellen van Rooijen
    Hubrecht Institute, Royal Netherlands Academy of Arts and Sciences and University Medical Center Utrecht, Utrecht, The Netherlands
    Dis Model Mech 3:343-53. 2010
    ..Importantly, they will allow for a cost-effective, non-invasive and efficient way to screen for novel pharmacological agents and combinatorial treatments...
  10. doi request reprint Accelerated perinecrotic outgrowth of colorectal liver metastases following radiofrequency ablation is a hypoxia-driven phenomenon
    Maarten W Nijkamp
    Department of Surgery, University Medical Center Utrecht, Utrecht, The Netherlands
    Ann Surg 249:814-23. 2009
    ....
  11. doi request reprint Mobility of the von Hippel-Lindau tumour suppressor protein is regulated by kinesin-2
    Dorus A Mans
    Laboratory of Experimental Oncology, Department of Medical Oncology, University Medical Center Utrecht, Utrecht, The Netherlands
    Exp Cell Res 314:1229-36. 2008
    ..From these data we suggest that mobility of a subcellular pool of pVHL is regulated by the ATP-dependent kinesin-2 motor. Kinesin-2 driven mobility of cytoplasmic pVHL might enable pVHL to function as a tumour suppressor...
  12. ncbi request reprint Allele-specific regulation of primary cilia function by the von Hippel-Lindau tumor suppressor
    Martijn P Lolkema
    Department of Medical Oncology, University Medical Center Utrecht, Heidelberglaan 100, Utrecht, The Netherlands
    Eur J Hum Genet 16:73-8. 2008
    ..Furthermore, reduction of cellular levels of VHL in this cell system was associated with fewer ciliated cells, suggesting a role for VHL in ciliary maintenance...
  13. ncbi request reprint Tumor suppression by the von Hippel-Lindau protein requires phosphorylation of the acidic domain
    Martijn P Lolkema
    Department of Medical Oncology, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands
    J Biol Chem 280:22205-11. 2005
    ..We propose that phosphorylation of the acidic domain plays a role in the regulation of proper fibronectin matrix deposition and that this may be relevant for the development of VHL-associated malignancies...
  14. doi request reprint Zebrafish mutants in the von Hippel-Lindau tumor suppressor display a hypoxic response and recapitulate key aspects of Chuvash polycythemia
    Ellen van Rooijen
    Department of Medical Oncology, University Medical Center, Utrecht, The Netherlands
    Blood 113:6449-60. 2009
    ..They will contribute to our understanding of hypoxic signaling, hematopoiesis, and VHL-associated disease progression...
  15. pmc Cytosolic p120-catenin regulates growth of metastatic lobular carcinoma through Rock1-mediated anoikis resistance
    Ron C J Schackmann
    Department of Medical Oncology, University Medical Center Utrecht, Utrecht, The Netherlands
    J Clin Invest 121:3176-88. 2011
    ....
  16. ncbi request reprint The von Hippel-Lindau tumour suppressor interacts with microtubules through kinesin-2
    Martijn P Lolkema
    Department of Medical Oncology, University Medical Center Utrecht, Heidelberglaan 100, rm F02 126, 3584 CX Utrecht, The Netherlands
    FEBS Lett 581:4571-6. 2007
    ..The interaction with kinesin-2 facilitates pVHL binding to microtubules. These data suggest that microtubule-dependent functions of pVHL are influenced by kinesin-2...
  17. ncbi request reprint Circulating mitochondrial nucleic acids have prognostic value for survival in patients with advanced prostate cancer
    Niven Mehra
    Department of Medical Oncology, University Medical Center Utrecht, 3508 GA Utrecht, The Netherlands
    Clin Cancer Res 13:421-6. 2007
    ..We assessed whether we could distinguish poor from good prognosis patients at presentation in our clinic by means of quantifying circulating cell-free mitochondrial and genomic nucleic acids in plasma...
  18. pmc Phase 1 study of combination treatment with PTK 787/ZK 222584 and cetuximab for patients with advanced solid tumors: safety, pharmacokinetics, pharmacodynamics analysis
    Marlies H G Langenberg
    Department of Medical Oncology, University Medical Center Utrecht, Utrecht, The Netherlands
    Neoplasia 12:206-13. 2010
    ..Cetuximab is a monoclonal antibody against epidermal growth factor (EGF) receptor. Combining inhibition of VEGF and EGF signaling might act additive or synergistically...
  19. ncbi request reprint Beta-amyloid (Abeta) causes detachment of N1E-115 neuroblastoma cells by acting as a scaffold for cell-associated plasminogen activation
    Onno Kranenburg
    Department of Medical Oncology, University Medical Center Utrecht, Utrecht, The Netherlands
    Mol Cell Neurosci 28:496-508. 2005
    ..Our results suggest that plasmin-mediated cell detachment could contribute to the pathological effects of Abeta in diseased brain...
  20. ncbi request reprint The von Hippel-Lindau tumor suppressor protein influences microtubule dynamics at the cell periphery
    Martijn P Lolkema
    Department of Medical Oncology, University Medical Center Utrecht, Utrecht, The Netherlands
    Exp Cell Res 301:139-46. 2004
    ..Here we propose a complementary method to directly measure VHL-induced subcellular changes in microtubule dynamics, which may serve as a tool to study the effect of MT binding proteins such as VHL...
  21. pmc Gender-related needs and preferences in cancer care indicate the need for an individualized approach to cancer patients
    Hester Wessels
    Department of Medical Oncology, University Medical Center Utrecht, 3508 GA Utrecht, The Netherlands
    Oncologist 15:648-55. 2010
    ..Multivariate regression analyses were performed with data obtained from medical oncology patients treated in seven Dutch hospitals, using the scales of the questionnaire as dependent variables...
  22. doi request reprint Chemotherapy enhances metastasis formation via VEGFR-1-expressing endothelial cells
    Laura G M Daenen
    Department of Medical Oncology, University Medical Center Utrecht, Utrecht, The Netherlands
    Cancer Res 71:6976-85. 2011
    ..Inhibition of VEGFR-1 function may therefore be used to counteract chemotherapy-induced retention of tumor cells within the metastatic niche, providing a novel level of tumor control in chemotherapy...
  23. pmc Constitutive integrin activation on tumor cells contributes to progression of leptomeningeal metastases
    Dieta Brandsma
    Department of Medical Oncology, University Medical Center Utrecht, Utrecht, The Netherlands
    Neuro Oncol 8:127-36. 2006
    ..We argue that an aberrantly regulated inside-out signaling pathway underlies constitutive integrin activation on the adherent leukemic cell population...
  24. ncbi request reprint Control of colorectal metastasis formation by K-Ras
    Niels Smakman
    Department of Surgery G04 228, University Medical Center Utrecht, Heidelberglaan 100, PO Box 85500, 3508GA Utrecht, The Netherlands
    Biochim Biophys Acta 1756:103-14. 2005
    ..In this review, we discuss the potential influence of mutant K-Ras on each of these phases. Furthermore, we have evaluated the clinical evidence that suggests a role for K-Ras in the formation of colorectal metastases...
  25. ncbi request reprint Vascular disrupting agents (VDAs) in anticancer therapy
    Laura G M Daenen
    Department of Medical Oncology, University Medical Center Utrecht, Utrecht, The Netherlands
    Curr Clin Pharmacol 5:178-85. 2010
    ..Clinical benefits are currently under investigation in a number of ongoing clinical trials, including randomized phase III trials...
  26. ncbi request reprint Progenitor marker CD133 mRNA is elevated in peripheral blood of cancer patients with bone metastases
    Niven Mehra
    Department of Medical Oncology and Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands
    Clin Cancer Res 12:4859-66. 2006
    ....
  27. ncbi request reprint Target practice: lessons from phase III trials with bevacizumab and vatalanib in the treatment of advanced colorectal cancer
    Maartje Los
    Department of Medical Oncology, University Medical Center Utrecht, Utrecht, The Netherlands
    Oncologist 12:443-50. 2007
    ..In addition, we discuss the adverse effects of bevacizumab and vatalanib and the clinical management of the side effects...
  28. ncbi request reprint Circulating CD95-ligand as a potential prognostic marker for recurrence in patients with synchronous colorectal liver metastases
    Frederik J H Hoogwater
    Department of Surgery, G 04 228, University Medical Centre Utrecht, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands
    Anticancer Res 31:4507-12. 2011
    ..To assess whether circulating soluble CD95 ligand (sCD95L) levels are associated with recurrence-free survival (RFS) in patients with synchronous colorectal liver metastases...
  29. doi request reprint Genetic analysis of von Hippel-Lindau disease
    Morgan Nordstrom-O'Brien
    Department of Medical Oncology, University Medical Center Utrecht, Universiteitsweg 100, Utrecht, The Netherlands
    Hum Mutat 31:521-37. 2010
    ..This easy-to-use compilation of VHL mutations is intended to facilitate research and function as a necessary adjunct for physicians when providing patient information...
  30. doi request reprint All along the watchtower: is the cilium a tumor suppressor organelle?
    Dorus A Mans
    Department of Medical Oncology, University Medical Center Utrecht, The Netherlands
    Biochim Biophys Acta 1786:114-25. 2008
    ..Furthermore, we predict that we are just now seeing the tip of the iceberg, and that the list of cancers associated with altered ciliary signalling will grow exponentially in the next few years...
  31. pmc Phase 1/2 study of atrasentan combined with pegylated liposomal doxorubicin in platinum-resistant recurrent ovarian cancer
    Petronella O Witteveen
    Department of Medical Oncology, University Medical Center Utrecht Cancer Center, Utrecht, The Netherlands
    Neoplasia 12:941-5. 2010
    ....
  32. ncbi request reprint Ischemia/reperfusion accelerates the outgrowth of hepatic micrometastases in a highly standardized murine model
    Jarmila D W van der Bilt
    Laboratory of Experimental Oncology, Department of Surgery, University Medical Center Utrecht, The Netherlands
    Hepatology 42:165-75. 2005
    ..In conclusion, I/R is a strong stimulus of recurrent intrahepatic tumor growth. Measures to prevent I/R-induced late tissue necrosis cross-protect against this phenomenon...
  33. ncbi request reprint Phase I clinical evaluation of weekly administration of the novel vascular-targeting agent, ZD6126, in patients with solid tumors
    Laurens V Beerepoot
    Department of Medical Oncology, University Medical Center Utrecht, Utrecht, The Netherlands
    J Clin Oncol 24:1491-8. 2006
    ..This leads to cell detachment and tumor vessel congestion, resulting in extensive central necrosis in a range of tumor xenograft models. Results from a phase I dose-escalation study of ZD6126 are reported...
  34. doi request reprint Expression of nuclear FIH independently predicts overall survival of clear cell renal cell carcinoma patients
    Stephanie G C Kroeze
    Department of Urology, University Medical Center Utrecht, The Netherlands
    Eur J Cancer 46:3375-82. 2010
    ..Herein, we evaluate the significance of upstream proteins directly regulating the HIF pathway; the prolyl hydroxylases domain proteins (PHD)1, 2 and 3 and factor-inhibiting HIF (FIH), as prognostic markers for ccRCC...
  35. doi request reprint Mesenchymal stem cells induce resistance to chemotherapy through the release of platinum-induced fatty acids
    Jeanine M L Roodhart
    Department of Medical Oncology, University Medical Center Utrecht, The Netherlands
    Cancer Cell 20:370-83. 2011
    ..Our findings show that MSCs are potent mediators of resistance to chemotherapy and reveal targets to enhance chemotherapy efficacy in patients...
  36. ncbi request reprint CSF protein profiling using Multiplex Immuno-assay: A potential new diagnostic tool for leptomeningeal metastases
    Dieta Brandsma
    Department of Neurology, G03 228, University Medical Center Utrecht, PO Box 85500, 3584 Utrecht, CX, The Netherlands
    J Neurol 253:1177-84. 2006
    ..More sensitive tools are needed to diagnose LM. We measured a profile of proteins involved in adhesion and inflammation in the CSF of LM and control patients and determined their potential diagnostic value for LM...
  37. ncbi request reprint The molecular basis of class side effects due to treatment with inhibitors of the VEGF/VEGFR pathway
    Jeanine M Roodhart
    Department of Medical Oncology F02 126, University Medical Center Utrecht, Utrecht, The Netherlands
    Curr Clin Pharmacol 3:132-43. 2008
    ..It has also provided new insight into the physiological role of this pathway in various organs. Integrating the knowledge in daily oncological practice will be a challenge for the future...
  38. ncbi request reprint Activated vitronectin as a target for anticancer therapy with human antibodies
    Haiko J Bloemendal
    Department of Medical Oncology, University Medical Center Utrecht, Heidelberglaan 100, HP F02 126, 3584 CX Utrecht, The Netherlands
    Cancer Immunol Immunother 53:799-808. 2004
    ..Our results establish activated vitronectin as a potential target for tumor therapy in humans...
  39. ncbi request reprint The role of the fibrinolytic system in corneal angiogenesis
    J Mathijs Vogten
    Department of Surgery, University Medical Center Utrecht, Utrecht, The Netherlands
    Angiogenesis 6:311-6. 2003
    ..Our results corroborate earlier findings that angiogenesis in the mouse cornea is dependent on PAI-1 and plasminogen. The absence of tPA, uPA or TAFI did not affect the formation of new vessels in the cornea...
  40. ncbi request reprint VEGF as a target of therapy in gastrointestinal oncology
    Maartje Los
    Department of Surgery, University Medical Center Utrecht, Utrecht, The Netherlands
    Dig Surg 22:282-93. 2005
    ..We will discuss the biology of the VEGF receptor/ligand signaling system and give an overview of the current approaches for therapy in gastrointestinal cancer targeting the VEGF signaling pathway...
  41. ncbi request reprint Circulating endothelial cells in cancer patients do not express tissue factor
    Laurens V Beerepoot
    Laboratory of Experimental Oncology, Department of Medical Oncology, HP F02 126, University Medical Center Utrecht, Heidelberglaan 100, PO Box 85500, 3508 GA, The Netherlands
    Cancer Lett 213:241-8. 2004
    ..TF-antigen expression was undetectable. CECs isolated from cancer patients do not express TF. CECs can generate functional TF after stimulation and may therefore play a role in (intratumoral) coagulation induction and tumor angiogenesis...
  42. ncbi request reprint Response of rat prostate and lung tumors to ionizing radiation combined with the angiogenesis inhibitor AMCA
    Henk B Kal
    Department of Radiotherapy, University Medical Centre, Utrecht, The Netherlands
    Strahlenther Onkol 180:798-804. 2004
    ..To determine whether radiation combined with Trans-4-AminoMethyl Cyclohexane carboxylic Acid (AMCA, or tranexamic acid, Cyklokapron) results in a better tumor response than radiation alone...
  43. doi request reprint Effective strategies for management of hypertension after vascular endothelial growth factor signaling inhibition therapy: results from a phase II randomized, factorial, double-blind study of Cediranib in patients with advanced solid tumors
    Marlies H G Langenberg
    Medical Oncology, University Medical Center Utrecht, PO Box 85500, 3508 GA Utrecht, The Netherlands
    J Clin Oncol 27:6152-9. 2009
    ..This protocol is included in all ongoing cediranib clinical studies...
  44. ncbi request reprint Symptom prevalence in patients with incurable cancer: a systematic review
    Saskia C C M Teunissen
    Department of Medical Oncology, University Medical Center, Utrecht, The Netherlands
    J Pain Symptom Manage 34:94-104. 2007
    ..Proper attention to symptom burden and suffering should be the basis for individually tailored treatment aimed at improving or maintaining quality of life of patients in their last period of life...
  45. doi request reprint Emerging drugs for esophageal cancer
    Marjolein Y V Homs
    University Medical Center Utrecht, Department of Medical Oncology, P O Box 85500, 3508 GA Utrecht, The Netherlands
    Expert Opin Emerg Drugs 14:329-39. 2009
    ..Cancer of the esophagus and gastro-esophageal junction is a disorder with a poor prognosis and increasing incidence...
  46. ncbi request reprint Do antiangiogenic protein fragments have amyloid properties?
    Martijn F B G Gebbink
    Labortory of Thrombosis and Hemostasis, Department of Hematology, G03 647, University Medical Centre Utrecht, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands
    Blood 104:1601-5. 2004
    ..The hypothesis provides new insights in the potential mechanisms of these angiogenesis inhibitors and offers opportunities to improve their use...
  47. ncbi request reprint Stimulation of angiogenesis by Ras proteins
    Onno Kranenburg
    Department of Surgery, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands
    Biochim Biophys Acta 1654:23-37. 2004
    ..In addition, tumor cell-activated stromal cells also contribute to the stimulation of angiogenesis by further enhancing the production and secretion of pro-angiogenic factors into the tumor stroma...
  48. ncbi request reprint Angiostatin inhibits experimental liver fibrosis in mice
    J Mathys Vogten
    Department of Surgery, University Medical Center Utrecht, PO Box 85500, 3508 GA Utrecht, The Netherlands
    Int J Colorectal Dis 19:387-94. 2004
    ..We hypothesized that angiostatin can inhibit pathological vessel growth and, consequently, the development of hepatic fibrosis...
  49. ncbi request reprint MR imaging of mouse leptomeningeal metastases
    Dieta Brandsma
    Department of Neurology, University Medical Center Utrecht, Utrecht, The Netherlands
    J Neurooncol 68:123-30. 2004
    ..Our data further suggest that LM are more clearly visualized using T1 weighted Gd-DTPA enhanced subtraction imaging than T2 weighted imaging...
  50. ncbi request reprint Impaired flow-induced dilation in mesenteric resistance arteries from receptor protein tyrosine phosphatase-mu-deficient mice
    Elianne A Koop
    Department of Medical Oncology, University Medical Centre Utrecht, Utrecht, The Netherlands
    Am J Physiol Heart Circ Physiol 288:H1218-23. 2005
    ..Our results imply that RPTPmu is involved in the mechanotransduction or accessory signaling pathways that control shear stress responses in mesenteric resistance arteries...
  51. pmc LRRC50, a conserved ciliary protein implicated in polycystic kidney disease
    Ellen van Rooijen
    Hubrecht Institute, Developmental Biology and Stem Cell Research, University Medical Center Utrecht, Utrecht, Netherlands
    J Am Soc Nephrol 19:1128-38. 2008
    ....
  52. ncbi request reprint Fibronectin is a hypoxia-independent target of the tumor suppressor VHL
    Hans A R Bluyssen
    Department of Medical Oncology, University Medical Center Utrecht, P O Box 85500, 3500 GA, Utrecht, The Netherlands
    FEBS Lett 556:137-42. 2004
    ..Thus regulation of fibronectin deposition by VHL occurs at the transcriptional level, irrespective of oxygen levels...
  53. ncbi request reprint Recombinant human angiostatin by twice-daily subcutaneous injection in advanced cancer: a pharmacokinetic and long-term safety study
    Laurens V Beerepoot
    Department of Medical Oncology, University Medical Center Utrecht, 3508 GA Utrecht, The Netherlands
    Clin Cancer Res 9:4025-33. 2003
    ..A clinical study was performed to evaluate the pharmacokinetics (PK) and toxicity of three dose levels of the angiogenesis inhibitor recombinant human (rh) angiostatin when administered twice daily by s.c. injection...
  54. ncbi request reprint Tumor suppressors APC and VHL: gatekeepers of the intestine and kidney
    Rachel H Giles
    Department Medical Oncology, University Medical Center Utrecht, Utrecht, The Netherlands
    Prog Mol Subcell Biol 40:151-81. 2005